[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@AceStocks88 "@stockplaymaker1 $LYRA low float (1.12M) low OS (1.64M) biotech w/ Phase X asset for rhino sinusitis. Cash runway into 2026. Former runner to near XX. Market cap 15M"
X Link @AceStocks88 2025-10-11T04:33Z XXX followers, XXX engagements

"@coff_free @SarwanJohn I like $LYRA as well. It has an active Phase X asset; cash runway into 2026 + just 1.6ish Million OS. Float just over 1M"
X Link @AceStocks88 2025-10-10T15:13Z XXX followers, XXX engagements

"@stockplaymaker1 $LYRA under the radar biotech IMO. Market Cap of 12.4M; 1.6M OS; 1.2ishM Float. Has Active Phase X asset that ALREADY had one successful trial. Working with FDA on new trial to address design issue. Former mover from X to around XX. $PRAX $MIRA $VIVK $SPRB $TTRX"
X Link @AceStocks88 2025-10-16T16:56Z XXX followers, XXX engagements

"@MMatters22596 Agree this is a good time for biotech with rate cuts (hopefully) & better access to financing. More consolidation and M & A activity in space too. Like late stage + commercial in particular. One example is $LYRA w/ Ph3 asset and a successful trial already. Many though"
X Link @AceStocks88 2025-10-12T23:00Z XXX followers, XXX engagements

"$LYRA reminds me of $SNSE. Market Cap of 11.8M; 1.6M OS; 1.2ishM Float. Has Active Phase X asset that ALREADY had one successful trial. Working with FDA on new trial to address design issue. Former mover from X to around XX. Just need updates. $PRAX $MIRA $VIVK $SPRB $TTRX"
X Link @AceStocks88 2025-10-17T12:53Z XXX followers, XX engagements

"$LYRA under the radar biotech IMO. Market Cap of 12.4M; 1.6M OS; 1.2ishM Float. Has Active Phase X asset that ALREADY had one successful trial. Working with FDA on new trial to address design issue. Former mover from X to around XX. $PRAX $MIRA $VIVK $SPRB $TTRX"
X Link @AceStocks88 2025-10-17T04:06Z XXX followers, XX engagements

"@Hedgenomix @stockplaymaker1 😂. I dont think there are too many retail owners but its a sleeper IMO. With low OS I think a market cap of 11M is diabolical for a co. with an asset in Phase X for something as common as sinusitis. They have to do one more trial due to a design issue but I like $LYRA here"
X Link @AceStocks88 2025-10-17T22:46Z XXX followers, XX engagements

"@SuperDuperInvst If $LYRA gets partnership news for financing Ph3 trial or other big news it might. 1.6M OS Biotech"
X Link @AceStocks88 2025-10-15T20:10Z XXX followers, XXX engagements

"@MMatters22596 $LYRA"
X Link @AceStocks88 2025-10-12T03:49Z XXX followers, XXX engagements

"@MoonMarket_ $LYRA low float (1.12M) low OS (1.64M) biotech w/ Phase X asset for rhino sinusitis. Cash runway into 2026. Former runner to near XX. Market cap 15M"
X Link @AceStocks88 2025-10-11T16:44Z XXX followers, XXX engagements

"@stockplaymaker1 $LYRA low float (1.12M) low OS (1.64M) biotech w/ Phase X asset for rhino sinusitis. Cash runway into 2026. Former runner to near XX. Market cap 15M"
X Link @AceStocks88 2025-10-11T16:43Z XXX followers, XXX engagements

"@TT_stocks_ I like $LYRA for a watch anyway. Has an active Phase X asset and previously ran from X to XX. FDA wants one more trial but still relatively cheap here. 1.6M OS"
X Link @AceStocks88 2025-10-15T20:07Z XXX followers, XXX engagements

"@stockplaymaker1 $LYRA small float bio worth watching w/ Phase X assets and sub 15M market cap. 1.64M OS; 1.12M float"
X Link @AceStocks88 2025-10-08T17:45Z XXX followers, XXX engagements